Abstract:Atopic dermatitis (AD) is a common, chronic and relapsing inflammatory skin disease with various clinical presentations and combinations of symptoms. The pathophysiology of AD is complex and multifactorial. There are several factors involved in the etiopathogenesis of AD including structural and immunological epidermal barrier defect, imbalance of the skin microbiome, genetic background and environmental factors. Alterations in structural proteins, lipids, proteases, and their inhibitors, lead to the impairment of the stratum corneum which is associated with the increased skin penetration and transepidermal water loss. The elevated serum immunoglobulin E levels and blood eosinophilia have been shown in the majority of AD patients. Type 2 T-helper cell immune pathway with increased expression of interleukin (IL)-4, IL-5, and IL-13, has an important role in the etiopathogenesis of AD. Both T cells and keratinocytes contribute to epidermal barrier impairment in AD via a dynamic interaction of cytokines and chemokines. The skin microbiome is another factor of relevance in the etiopathogenesis of AD. It has been shown that during AD flares, Staphylococcus aureus ( S. aureus ) colonization increased, while Staphylococcus epidermidis ( S. epidermidis ) decreased. On the contrary, S. epidermidis and species of Streptococcus , Corynebacterium and Propionibacterium increased during the remision phases. However, it is not clear whether skin dysbiosis is one of the symptoms or one of the causes of AD. There are several therapeutic options, targeting these pathways which play a critical role in the etiopathogenesis of AD. Although topical steroids are the mainstay of the treatment of AD, new biological therapies including IL-4, IL-13, and IL-31 inhibitors, as well as Janus kinase inhibitors (JAKi), increasingly gain more importance with new advances in the therapy of AD. In this review, we summarize the role of immunological and structural epidermal barrier dysfunction, immune abnormalities, impairment of lipids, filaggrin mutation and skin microbiome in the etiopathogenesis of AD, as well as the therapeutic options for AD and their effects on these abnormalities in AD skin.

Profile of skin barrier proteins and cytokines in adults with atopic dermatitis

Cellular and molecular mechanisms in atopic dermatitis

The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update

Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis

Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives

Molecular Biology of Atopic Dermatitis

Skin Barrier Abnormalities in Atopic Dermatitis

Association between barrier impairment and skin microbiota in atopic dermatitis from a global perspective: Unmet needs and open questions

Pathophysiology of atopic dermatitis: Clinical implications.

Understanding the Pathophysiology of Atopic Dermatitis – insights into Immune Dysregulation and Skin Barrier Dysfunction

Update on the pathogenesis of atopic dermatitis

Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options

Recent Advancements in the Atopic Dermatitis Mechanism

Exploring the skin microbiome in atopic dermatitis pathogenesis and disease modification

Abnormal epidermal barrier in the pathogenesis of atopic dermatitis

Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches

Constant Vigilance! Managing Threats to the Skin Barrier

The Roles of Innate Immune Cells in Atopic Dermatitis

Update on the Pathogenesis and Therapy of Atopic Dermatitis

Significance of Skin Barrier Dysfunction in Atopic Dermatitis

Skin Barrier Function and Microtopography in Patients with Atopic Dermatitis